

### Amendment to the Claims

The status of claims 1-44 after amendment is listed below.

Claim 1-45. Canceled.

Rule 1.28  
Claim <sup>45</sup>46 (New) An immunological adjuvant composition useful for enhancing the immune response against an active agent, comprising:

a first adjuvant consisting essentially of amorphous calcium phosphate particles and a liquid component, said first adjuvant formulated as an injectable paste having a solids content of greater than or equal to 40 wt%.

D 1  
Claim <sup>46</sup>47 (New) An immunological composition useful for enhancing the immune response against an active agent, comprising:

a first adjuvant comprising amorphous or nanocrystalline calcium phosphate particles and a liquid component, said first adjuvant formulated as an injectable paste having a solids content of greater than or equal to 40 wt%; and

Sub E 14  
an active agent selected from the group consisting of antigens, bacteria or viruses or fragments thereof, haptens, allergens and immunogens.

R-126  
Claim <sup>47</sup>48 (New) The composition of claim 46 or 47, wherein said particles have a diameter between 0.1 nm and 900 nm.

Claim <sup>48</sup>49 (New) The composition of claim 48, wherein 25-100% by weight of said composition consists of said particles having a diameter between 0.1 nm and 900 nm.

Claim <sup>49</sup>50 (New) The composition of claim 46 or 47 further comprising a second adjuvant.

Claim <sup>50</sup>51 (New) The composition of claim 50, wherein said second adjuvant is selected from the group consisting of muramyl dipeptide, aluminum hydroxide, aluminum phosphate, hydroxyapatite, Incomplete Freund's Adjuvant, and Complete Freund's Adjuvant.

Claim <sup>51</sup>52 (New) The composition of claim 50, wherein the first and second adjuvants are selected so as to elicit an immune response from targeted cells or cell types.

Claim <sup>52</sup>53. (New) The composition of claim 50, wherein the first and second adjuvants are selected so as to elicit an immune response from cells of the same type.

Claim <sup>53</sup>54. (New) The composition of claim 50, wherein the first and second adjuvants are selected so as to elicit an immune response from cells of different types.

Claim <sup>54</sup>55. (New) The composition of claim 50, further comprising an endogenous adjuvanticity enhancing means.

Claim <sup>55</sup>56. (New) The composition of claim 47 wherein the active agent comprises an antigen.

Claim <sup>56</sup>57. (New) The composition of claim 47 further comprising a cytokine.

Claim <sup>57</sup>58. (New) The composition of claim 53, wherein said cytokine is selected from the group consisting of IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-11, IL-13, G-CSF, IL-15, GM-CSF, OSM, LIF, IFN- $\gamma$ , IFN- $\alpha$ , IFN- $\beta$ , B7.1, B7.2, TNF- $\alpha$ , TNF- $\beta$ , LT- $\beta$ , CD40 ligand, Fas ligand, CD27 ligand, CD30 ligand, 4-1BBL, IL-8, MCP-1, MIP- $\alpha$ , MIP- $\beta$ , RANTES, TGF- $\beta$ , IL-1 $\alpha$ , IL-1 $\beta$ , IL-1 RA, IL-10, IL-12, and MIF.

Claim <sup>58</sup>59. (New) The composition of claim 47, wherein the nanocrystalline calcium phosphate comprises hydroxyapatite.

Claim <sup>59</sup>60. (New) A method for stimulating an immune response in a mammal, said method comprising:

administering to the mammal a composition comprising amorphous or nanocrystalline calcium phosphate particles and an active agent selected from the group consisting of antigens, bacteria or viruses or fragments thereof, haptens, allergens and immunogens, formulated as an injectable paste having a solids content of greater than or equal to 40 wt%.

Claim <sup>60</sup>61. A method for increasing immunogenicity of an antigen in a mammal, said method comprising:

co-administering both an antigen and a composition comprising amorphous calcium phosphate formulated as a hardenable, injectable paste having a solids content of greater than or equal to 40wt%.